The C-terminus of Hsp70-interacting protein promotes met receptor degradation

Journal of Thoracic Oncology

Volumn 6, Issue 4, 2011, Pages 679-687

  Jang, Kang Won ^a   Lee, Jeong Eun ^b   Kim, Sun Young ^b   Kang, Min Woong ^b   Na, Myung Hoon ^b   Lee, Choong Sik ^a   Song, Kyu Sang ^a   Lim, Seung Pyung ^b  

^a Chungnam National University   (South Korea)

^b Chungnam National University College of Medicine   (South Korea)

Author keywords

C terminus of Hsp70 Interacting Protein (CHIP); Met; Proteasomal degradation; Ubiquitination

Indexed keywords

HEAT SHOCK PROTEIN 70; SCATTER FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INVASION; CARBOXY TERMINAL SEQUENCE; CELL VIABILITY; DOWN REGULATION; FEMALE; HELA CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; REGULATORY MECHANISM; TUMOR GROWTH; TUMOR XENOGRAFT; UBIQUITINATION;

EID: 79953029117     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31820d9c7e     Document Type: Article

References (48)

1. Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2002;2:289-300. (Pubitemid 37328782)
2. Gentile A, Comoglio PM. Invasive growth: a genetic program. Int J Dev Biol 2004;48:451-456. (Pubitemid 39360395)
3. Lee CC, Putnam AJ, Miranti CK, et al. Overexpression of sprouty 2 inhibits HGF/SF-mediated cell growth, invasion, migration, and cytoki-nesis. Oncogene 2004;23:5193-5202. (Pubitemid 38980352)
4. Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-925. (Pubitemid 37493640)
5. Di Renzo MF, Narsimhan RP, Olivero M, et al. Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene 1991;6:1997-2003. (Pubitemid 21924039)
6. Gao CF, Vande Woude GF. HGF/SF-Met signaling in tumor progres-sion. CellRes 2005;15:49-51.
7. Bonifacino JS, Weissman AM. Ubiquitin and the control of protein fate in the secretory and endocytic pathways. Annu Rev Cell Dev Biol 1998;14:19-57. (Pubitemid 29001448)
8. Carpenter G. The EGF receptor: a nexus for trafficking and signaling. Bioessays 2000;22:697-707. (Pubitemid 30613301)
9. Jeffers M, Taylor GA, Weider KM, et al. Degradation of the Met Tyrosine Kinase Receptor by the Ubiquitin-Proteasome Pathway. Mol Cell Biol 1997;17:799-808. (Pubitemid 27044379)
10. Hammond DE, Urbe S, Vande Woude GF, et al. Down-regulation of MET, the receptor for hepatocyte growth factor. Oncogene 2001;20: 2761-2770. (Pubitemid 32549833)
11. Van kerkhof P, Govers R, Alves dos Santos CM, et al Endocytosis and degradation of the growth hormone receptor are proteasome-dependent. JBiol Chem 2000; 275: 1575-1580. (Pubitemid 30060771)
12. Connell P, Ballinger CA, Jiang J, et al. The co-chaperone CHIP regu-lates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol 2001;3:93-96. (Pubitemid 32114838)
13. Demand J, Albert S, Patterson C, et al. Cooperation of an ubiquitin domain protein and an E3 ubiquitin ligase during chaperone/proteasome coupling. Curr Biol 2001;11:1569-1577. (Pubitemid 32978521)
14. Zhou P, Fernandes N, Dodge IL, et al. ErbB2 degradation mediated by the co-chaperone protein CHIP. J Biol Chem 2003;278:13829-13837. (Pubitemid 36799921)
15. Ballinger CA, Connell P, Wu Y, et al. Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol Cell Biol 1999;19:4535-4545. (Pubitemid 29242026)
16. Carter S, Urbe S, Clague MJ. The Met receptor degradation pathway. Requirement for Lys48-linked polyubiquitin independent of proteasome activity. J Biol Chem 2004;279:52835-52839. (Pubitemid 40051783)
17. Peschard P, Ishiyama M, Lipkowitz S, et al. A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site re-quired for suppression of oncogenic activation. J Biol Chem 2004;279: 29565-29571. (Pubitemid 38915838)
18. Shattuck DL, Miller JK, Laederich M, et al. LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. Mol Cell Biol 2007;27:1934-1946.
19. Taher TE, Tjin EP, Beuling EA, et al. c-Cbl is involved in Met signaling in B cells and mediates hepatocyte growth factor-induced receptor ubiquitination. J Immunol 2002;169:3793-3800.
20. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. NEngl JMed 2004;350:2129-2139. (Pubitemid 38637993)
21. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304: 1497-1500. (Pubitemid 38720929)
22. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-13311. (Pubitemid 39209661)
23. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signal-ing. Science 2007;316:1039-1043. (Pubitemid 46799492)
24. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007;104: 20932-20937.
25. Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG. Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors. Lancet Oncol 2009;10:709-717.
26. Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG. The role of STATs in lung carcinogenesis: an emerging target for novel therapeu-tics. J Mol Med 2007;85:427-436. (Pubitemid 46701658)
27. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008;7:504-516. (Pubitemid 351767118)
28. Wang S, Pashtan I, Tsutsumi S, et al. Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors. Cell Cycle 2009;8: 2050-2056.
29. Atabey N, Gao Y, Yao ZJ, et al. Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morpho-genesis by antagonists of Grb2 Src homology 2 domain interactions. J Biol Chem 2001;276:14308-14314.
30. O'Toole JM, Rabenau KE, Burns K, et al. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. Cancer Res 2006;66:9162-9170. (Pubitemid 44521136)
31. Zhang Y, Kaplan-Lefko PJ, Rex K, et al. Identification of a novel recepteur d'origine nantais/c-MET small-molecule kinase inhibitor with antitumour activity in vivo. Cancer Res 2008;68:6680-6687.
32. Chan GK, Lutterbach BA, Pan BS, et al. High-throughput analysis of HGF-stimulated cell scattering. J Biomol Screen 2008;13:847-854.
33. Patane S, Pietrancosta N, Hassani H, et al. A new Met inhibitory-scaff old identified by a focused forward chemical biological screen. Biochem Biophys Res Commun 2008;375:184-189.
34. Stabile LP, Lyker JS, Huang L, et al. Inhibition of human non-small cell lung tumours by a c-MET antisense/U6 expression plasmid strategy. Gene Ther 2004;11:325-335. (Pubitemid 38220085)
35. Kim SJ, Johnson M, Koterba K, et al. Reduced c-MET expression by an adenovirus expressing a c-MET ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumour cells in an orthotopic nude mouse model. Clin Cancer Res 2003;9:5161-5170. (Pubitemid 37420030)
36. Chu SH, Feng DF, Zhang H, et al. c-Met-targeted RNA interference inhibits growth and metastasis of glioma U251 cells in vitro. JNeuroon-col 2009;93:183-189.
37. Lai AZ, Abella JV, Park M. Crosstalk in Met receptor oncogenesis. Trends CellBiol 2009;19:542-551.
38. Koga F, Tsutsumi S, Neckers LM. Low dose geldanamycin inhibits hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells. Cell Cycle 2007;6:1393-1402. (Pubitemid 47327975)
39. Maulik G, Kijima T, Ma PC, et al. Modulation of the c-Met/heatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 2002;8:620-627. (Pubitemid 34193985)
40. Xie Q, Gao CF, Shinomiya N, et al. Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion. Oncogene 2005;24:3697-3707. (Pubitemid 40826869)
41. Webb CP, Hose CD, Koochekpour S, et al. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor Met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res 2000;60:342-349. (Pubitemid 30070761)
42. Basso AD, Solit DB, Chiosis G, et al. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 is destabilized by inhibitors ofHsp90 function. J Biol Chem 2002;277:39858-39866. (Pubitemid 35190971)
43. Schulte TW, Blagosklonny MV, Romanova L, et al. Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEKmitogen-activated protein kinase signalling pathway Mol CellBiol 1996;16:5839-5845. (Pubitemid 26315105)
44. Lang SA, Moser C, Gaumann A, et al. Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-1 receptor sig-naling, disrupts an interleukin-6/signal-transducer and activator of tran-scription 3/hypoxia-inducible factor-1 alpha autocrine loop, and reduces orthotopic tumor growth. Clin Cancer Res 2007;13:6459-6468. (Pubitemid 350075036)
45. Fan M, Park A, Nephew KP. CHIP (Carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degrada-tion of estrogen receptor-α. Mol Endocrinol 2005;19:2901-2914. (Pubitemid 41697710)
46. Tan YH, Krishnaswamy S, Nandi S, et al. CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. PLoS ONE 2010;5:e8972.
47. Hammond DE, Carter S, McCullough J, et al. Endosomal dynamics of Met determine signaling output. Mol Biol Cell 2003;14:1346-1354. (Pubitemid 36547405)
48. Kajiro M, Hirota R, Nakajima Y, et al. The ubiquitin ligase CHIP acts as an upstream regulator of oncogenic pathways. Nat Cell Biol 2009; 11:312-319.